All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-03-22T12:10:05.000Z

EHA-SWG 2017 | Rare Lymphomas: CAR T-cells in Non-Hodgkin Lymphoma

Mar 22, 2017
Share:

Bookmark this article

On March 12th, at the EHA-SWG Rare Lymphomas Scientific Meeting 2017 in Barcelona, Spain, Marie José Kersten chaired a scientific session on ‘Fighting Lymphoma with T-cells’. The first presentation of this session was by Catherine Bollard, from The George Washington University, School of Medicine and Health Sciences, Bethesda, USA, on the topic of ‘CD19 CAR T-cells for Lymphoma’. Below are the key highlights from this presentation:

  • Over 15 studies open using CAR CD19-transduced T-cells in the US
  • First generation CAR T-cells had low persistence in patients
  • Second generation CARs developed which include an additional domain, either:
    • CD28
    • 41BBL
    • OX40L
  • Second generation CAR T-cell therapy shown to have increased proliferation and persistence vs. first generation within the same B-cell lymphoma patients
  • Multiple companies are currently working on different second-generation CAR constructs e.g. Kite, Novartis, Juno, and Bluebird Bio
  • Persistence of CAR T-cells correlated with response
  • Pre-CAR T-cell lymphodepleting chemotherapy with fludarabine and cyclophosphamide improves CAR T-cell proliferation and persistence
  • Cytokine release syndrome remains an important adverse event to monitor and manage in patients undergoing CAR T-cell therapy

To summarize, Catherine Bollard presented data detailing the differences between first and second-generation CAR T-cell technology, outlined the perceived importance of CAR T-cell persistence, identified the main CAR T-cell constructs currently being used, and outlined potential issues in the applicability of this treatment. Studies are ongoing, and long-term follow-up data is eagerly being awaited.

  1. Bollard C. CAR T-cells. 2017 Mar 12. EHA-SWG Rare Lymphomas. Barcelona, Spain.

More about...

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox